T. Rowe Price Associates
SNY icon

T. Rowe Price Associates’s Sanofi SNY Stock Holding History

T. Rowe Price Associates’s Portfolio SNY Stock Details SNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.32M Sell
54,377
-1,558,998
-97% -$69.7M ﹤0.01% 1933
2026
Q1 		$77.7M Sell
1,613,375
-1,260,284
-44% -$58.8M 0.01% 662
2025
Q4 		$139M Sell
2,873,659
-2,999,880
-51% -$149M 0.02% 559
2025
Q3 		$277M Buy
5,873,539
+347,794
+6% +$16.8M 0.03% 381
2025
Q2 		$267M Sell
5,525,745
-5,511,133
-50% -$282M 0.03% 377
2025
Q1 		$612M Buy
11,036,878
+193,196
+2% +$10.5M 0.08% 241
2024
Q4 		$523M Buy
10,843,682
+5,091,304
+89% +$259M 0.06% 259
2024
Q3 		$332M Buy
5,752,378
+3,890,678
+209% +$210M 0.04% 346
2024
Q2 		$90.3M Buy
1,861,700
+536,838
+41% +$25.9M 0.01% 568
2024
Q1 		$64.4M Sell
1,324,862
-32,835
-2% -$1.6M 0.01% 655
2023
Q4 		$67.5M Buy
1,357,697
+14,358
+1% +$702K 0.01% 621
2023
Q3 		$72.1M Sell
1,343,339
-35,589
-3% -$1.9M 0.01% 581
2023
Q2 		$74.3M Sell
1,378,928
-664,489
-33% -$35.8M 0.01% 594
2023
Q1 		$111M Sell
2,043,417
-833,389
-29% -$40.5M 0.02% 491
2022
Q4 		$139M Sell
2,876,806
-9,420,070
-77% -$413M 0.02% 437
2022
Q3 		$472M Sell
12,296,876
-4,947,478
-29% -$220M 0.08% 234
2022
Q2 		$863M Buy
17,244,354
+10,684,509
+163% +$567M 0.11% 199
2022
Q1 		$337M Buy
6,559,845
+417,741
+7% +$21.6M 0.03% 405
2021
Q4 		$308M Buy
6,142,104
+529,723
+9% +$26.2M 0.03% 445
2021
Q3 		$271M Buy
5,612,381
+1,229,367
+28% +$62.5M 0.03% 462
2021
Q2 		$231M Sell
4,383,014
-1,642
-0% -$85.7K 0.02% 523
2021
Q1 		$217M Buy
4,384,656
+1,376,204
+46% +$66.1M 0.02% 533
2020
Q4 		$146M Buy
3,008,452
+1,593,595
+113% +$78.6M 0.02% 606
2020
Q3 		$71M Buy
1,414,857
+165,341
+13% +$8.51M 0.01% 760
2020
Q2 		$63.8M Buy
+1,249,516
New +$60.7M 0.01% 770
2014
Q1 		– Sell
-5,000
Closed -$268K – 2514
2013
Q4 		$268K Buy
+5,000
New +$258K ﹤0.01% 2194

Other funds holding SNY

Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
MIP
Mondrian Investment Partners London, United Kingdom $6.48B AUM 18.36% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return

T. Rowe Price Associates's SNY Position: Q2 2026 in Review

T. Rowe Price Associates reduced its Sanofi (SNY) stake by 97% in Q2 2026, selling an estimated $69.7M and leaving 54,377 shares worth $2.32M. The position accounts for ﹤0.01% of the portfolio, ranked #1933.

T. Rowe Price Associates first reported a position in SNY in Q4 2013 and has held it in 26 quarters since. The position peaked at $863M in Q2 2022. 715 funds tracked by Wall St. Rank hold SNY as of Q2 2026.

  • T. Rowe Price Associates held 54,377 shares of Sanofi worth $2.32M as of Q2 2026.
  • T. Rowe Price Associates sold 1,558,998 Sanofi shares in Q2 2026, an estimated $69.7M.
  • Sanofi made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #1933 holding.
  • T. Rowe Price Associates first reported a position in Sanofi in Q4 2013 and has held it in 26 quarters since.
  • T. Rowe Price Associates's Sanofi position peaked at $863M in Q2 2022.
  • 715 funds tracked by Wall St. Rank held Sanofi as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.